# Vasculitis and related conditions **Type:** Topics **Canonical URL:** https://scholariq.org/topics/vasculitis-and-related-conditions/ ## Facts | Field | Value | | --- | --- | | Description | This cluster of papers focuses on the classification, diagnosis, and management of various vasculitides, including ANCA-associated vasculitis, giant cell arteritis, polyarteritis nodosa, Churg-Strauss syndrome, and Takayasu arteritis. It discusses the use of rituximab and other therapies, as well as EULAR recommendations for the management of vasculitis. Additionally, it explores the role of imaging in diagnosing and monitoring vasculitic diseases. | | Domain | Health Sciences | | Field | Medicine | | OpenAlex ID | t10697 | | Works | 547 | ## Topic papers all Showing 15 of 547. - [2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides](https://scholariq.org/papers/2012-revised-international-chapel-hill-consensus-conference-nomenclature-of-2/) - [Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II](https://scholariq.org/papers/estimates-of-the-prevalence-of-arthritis-and-other-rheumatic-conditions-in-the/) - [Differential Diagnosis of Glomerular Disease: A Systematic and Inclusive Approach](https://scholariq.org/papers/differential-diagnosis-of-glomerular-disease-a-systematic-and-inclusive-approach/) - [Nomenclature of Systemic Vasculitides](https://scholariq.org/papers/nomenclature-of-systemic-vasculitides/) - [Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis/) - [M-Type Phospholipase A 2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy](https://scholariq.org/papers/m-type-phospholipase-a-sub-2-sub-receptor-as-target-antigen-in-idiopathic/) - [The Classification of Glomerulonephritis in Systemic Lupus Erythematosus Revisited](https://scholariq.org/papers/the-classification-of-glomerulonephritis-in-systemic-lupus-erythematosus/) - [Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis/) - [Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis](https://scholariq.org/papers/impairment-of-neutrophil-extracellular-trap-degradation-is-associated-with-lupus/) - [Anti-Neutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic Glomerulonephritis](https://scholariq.org/papers/anti-neutrophil-cytoplasmic-autoantibodies-with-specificity-for-myeloperoxidase/) - [Trial of Tocilizumab in Giant-Cell Arteritis](https://scholariq.org/papers/trial-of-tocilizumab-in-giant-cell-arteritis/) - [Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies](https://scholariq.org/papers/development-and-validation-of-a-consensus-methodology-for-the-classification-of/) - [A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies](https://scholariq.org/papers/a-randomized-trial-of-maintenance-therapy-for-vasculitis-associated-with/) - [Banff 2013 Meeting Report: Inclusion of C4d-Negative Antibody-Mediated Rejection and Antibody-Associated Arterial Lesions](https://scholariq.org/papers/banff-2013-meeting-report-inclusion-of-c4d-negative-antibody-mediated-rejection/) - [Small-Vessel Vasculitis](https://scholariq.org/papers/small-vessel-vasculitis/) ## Topic primary papers Showing 15 of 227. - [2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides](https://scholariq.org/papers/2012-revised-international-chapel-hill-consensus-conference-nomenclature-of-2/) - [Nomenclature of Systemic Vasculitides](https://scholariq.org/papers/nomenclature-of-systemic-vasculitides/) - [Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-for-anca-associated-vasculitis/) - [Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis](https://scholariq.org/papers/rituximab-versus-cyclophosphamide-in-anca-associated-renal-vasculitis/) - [Anti-Neutrophil Cytoplasmic Autoantibodies with Specificity for Myeloperoxidase in Patients with Systemic Vasculitis and Idiopathic Necrotizing and Crescentic Glomerulonephritis](https://scholariq.org/papers/anti-neutrophil-cytoplasmic-autoantibodies-with-specificity-for-myeloperoxidase/) - [Trial of Tocilizumab in Giant-Cell Arteritis](https://scholariq.org/papers/trial-of-tocilizumab-in-giant-cell-arteritis/) - [Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies](https://scholariq.org/papers/development-and-validation-of-a-consensus-methodology-for-the-classification-of/) - [A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies](https://scholariq.org/papers/a-randomized-trial-of-maintenance-therapy-for-vasculitis-associated-with/) - [Small-Vessel Vasculitis](https://scholariq.org/papers/small-vessel-vasculitis/) - [2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides](https://scholariq.org/papers/2012-revised-international-chapel-hill-consensus-conference-nomenclature-of/) - [Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro.](https://scholariq.org/papers/anti-neutrophil-cytoplasmic-autoantibodies-induce-neutrophils-to-degranulate-and/) - [Modification and validation of the Birmingham Vasculitis Activity Score (version 3)](https://scholariq.org/papers/modification-and-validation-of-the-birmingham-vasculitis-activity-score-version/) - [EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis](https://scholariq.org/papers/eular-era-edta-recommendations-for-the-management-of-anca-associated-vasculitis/) - [Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis](https://scholariq.org/papers/randomized-trial-of-plasma-exchange-or-high-dosage-methylprednisolone-as/) - [Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis](https://scholariq.org/papers/mepolizumab-or-placebo-for-eosinophilic-granulomatosis-with-polyangiitis/) --- Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.